Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

Oncogene

Volumn 31, Issue 50, 2012, Pages 5193-5200

  Schonherr C ^a   Ruuth, K ^a   Kamaraj, S ^a   Wang, C L ^b   Yang, H L ^b   Combaret, V ^c   Djos, A ^d   Martinsson, T ^d   Christensen, J G ^e   Palmer, R H ^a   Hallberg, B ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b BEIJING FORESTRY UNIVERSITY   (China)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e La Jolla Laboratories ^*  (United States)

Author keywords

ALK; anaplastic lymphoma kinase; MYCN; neuroblastoma; transcription factor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; MESSENGER RNA; MYCN PROTEIN; NVPTAE 684; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NERVE CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; RNA TRANSCRIPTION; TRANSCRIPTION INITIATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOHEXIMIDE; DOWN-REGULATION; HUMANS; MICE; MUTATION; NEUROBLASTOMA; NIH 3T3 CELLS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PC12 CELLS; PROMOTER REGIONS, GENETIC; PROTEIN BIOSYNTHESIS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84871212519     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.12     Document Type: Article

References (49)

1. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-4362.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
4. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-1033.
5. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007; 46: 1098-1108.
6. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23: 2280-2299.
7. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416: 153-159.
8. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
9. George RE, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978.
10. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
11. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
12. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-361.
13. Goodman LA, Liu BC, Thiele CJ, Schmidt ML, Cohn SL, Yamashiro JM et al. Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis 1997; 15: 130-139.
14. Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H et al. MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol 2000; 476: 239-248.
15. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
16. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-2995.
17. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1259.
18. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005; 9: 327-338.
19. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 2006; 26: 2832-2844.
20. Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A et al. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J 2009; 28: 500-512.
21. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67-78.
22. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006; 66: 8139-8146.
23. Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 2011; 21: 4-11.
24. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17(11 Reviews): 1343-1352.
25. Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G et al. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget 2010; 1: 278-288.
26. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC et al. Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor. N Engl J Med 2010; 363: 1727-1733.
27. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. N Engl J Med 2010; 363: 1734-1739.
28. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6(12 Part 1): 3314-3322.
29. Hallberg B, Palmer RH. Crizotinib-latest champion in the cancer wars? N Engl J Med 2010; 363: 1760-1762.
30. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic Lymphoma Kinase Inhibition in Nonâh"Small-Cell Lung Cancer. N Engl J Med 2010; 363: 1693-1703.
31. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-4417.
32. Hallberg B, Palmer RH. ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med Reports 2011; 3: (doi:10.3410/M3-21).
33. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007; 104: 270-275.
34. Li Y, Ye X, Liu J, Zha J, Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011; 13: 1-11.
35. Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapy. Cancer Res 2011; 71: 98-105.
36. Schonherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH et al. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J 2011; 440: 405-413.
37. Schonherr C, Yang HL, Vigny M, Palmer RH, Hallberg B. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. Oncogene 2010; 29: 2817-2830.
38. Combaret V, Turc-Carel C, Thiesse P, Rebillard AC, Frappaz D, Haus O et al. Sensitive detection of numerical and structural aberrations of chromosome 1 in neuroblastoma by interphase fluorescence in situ hybridization. Comparison with restriction fragment length polymorphism and conventional cytogenetic analyses. Int J Cancer 1995; 61: 185-191.
39. Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A et al. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 2003; 141: 32-42.
40. Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 2008; 283: 3743-3750.
41. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002; 2: 377-386.
42. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27: 2910-2922.
43. Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003; 104: 233-237.
44. Obrig TG, Culp WJ, Mckeehan WL, Hardesty B. Mechanism by Which Cycloheximide and Related Glutarimide Antibiotics Inhibit Peptide Synthesis on Reticulocyte Ribosomes. J Biol Chem 1971; 246: 174-181.
45. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8: 397-403.
46. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316-2321.
47. Berthier A, Piqueras M, Villamon E, Berbegall A, Tadeo I, Castel V et al. Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors. Hum Pathol 2011; 42: 301-302.
48. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005; 280: 26039-26048.
49. Yang HL, Eriksson T, Vernersson E, Vigny M, Hallberg B, Palmer RH. The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. J Exp Zool B Mol Dev Evol 2007; 308: 269-282.